BE893789A - Agents anti-obesite - Google Patents

Agents anti-obesite

Info

Publication number
BE893789A
BE893789A BE0/208549A BE208549A BE893789A BE 893789 A BE893789 A BE 893789A BE 0/208549 A BE0/208549 A BE 0/208549A BE 208549 A BE208549 A BE 208549A BE 893789 A BE893789 A BE 893789A
Authority
BE
Belgium
Prior art keywords
obesity agents
obesity
agents
Prior art date
Application number
BE0/208549A
Other languages
English (en)
Original Assignee
Wyeth John & Brother Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth John & Brother Ltd filed Critical Wyeth John & Brother Ltd
Publication of BE893789A publication Critical patent/BE893789A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BE0/208549A 1981-07-07 1982-07-07 Agents anti-obesite BE893789A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8120961 1981-07-07

Publications (1)

Publication Number Publication Date
BE893789A true BE893789A (fr) 1983-01-07

Family

ID=10523079

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/208549A BE893789A (fr) 1981-07-07 1982-07-07 Agents anti-obesite

Country Status (6)

Country Link
US (1) US4451465A (fr)
JP (1) JPS5815915A (fr)
AU (1) AU558020B2 (fr)
BE (1) BE893789A (fr)
IT (1) IT1157288B (fr)
ZA (1) ZA824382B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases
US6344481B1 (en) 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US7504435B2 (en) * 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US7202222B2 (en) * 2003-01-06 2007-04-10 National Bioscience Corporation Methods for treatment of obesity and effective fat loss promotion
KR101167579B1 (ko) 2003-04-29 2012-07-27 오렉시젠 세러퓨틱스 인크. 체중감량용 조성물
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2008219585A1 (en) * 2007-02-27 2008-09-04 The Arizona Board Of Regents On Behalf Of The University Of Arizona Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome.
CA2725930A1 (fr) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Procedes pour traiter des pathologies des graisses viscerales
PL4104824T3 (pl) 2012-06-06 2025-11-12 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2200584A1 (de) * 1971-01-11 1972-07-27 Wyeth John & Brother Ltd Heterocyclische Verbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
GB1366133A (en) * 1971-01-11 1974-09-11 Wyeth John & Brother Ltd Fused ring indole derivatives
US4307234A (en) * 1978-09-11 1981-12-22 American Home Products Corp. Pyrimido[1,6-a]indole derivatives

Also Published As

Publication number Publication date
AU8516982A (en) 1983-01-13
IT8222209A0 (it) 1982-07-02
US4451465A (en) 1984-05-29
JPS5815915A (ja) 1983-01-29
IT1157288B (it) 1987-02-11
ZA824382B (en) 1984-02-29
AU558020B2 (en) 1987-01-15

Similar Documents

Publication Publication Date Title
BE893795A (fr) Inhalateur-doseur
FI822474A0 (fi) Papper innefattande en delvis inbaeddad remsa
AR228298A1 (es) Cubo-rompecabezas
AT382116B (de) Geraeuschgedaempftes schienenrad
BE889765A (fr) Stijgerelement
AT372860B (de) Schipaar
FI823667L (fi) Maethuvud foer infraroed fuktmaetare
BE893877A (fr) Mond-en tandverzorgingsmiddel
MA19539A1 (fr) N Acylaminophenylpyrazoles
IT1157288B (it) Agenti anti-obesita'
BE894481A (fr) Stromingsmeter
AT384100B (de) Drehrohrofen
BE891918A (fr) Draaibare schoorsteenkap
BE891837A (fr) Anthracycline-glycosides
FI822453L (fi) Cykellaos
AT379276B (de) Hoergeraet
AT385733B (de) Skibob
FI822019L (fi) Roentgenundersoekningsapparat
ATA183681A (de) Blockhaus
AT374656B (de) Maishaecksler
FI822721L (fi) Braensleinjektor speciellt foer foerbraenningsmotorer
BE893857A (fr) Comptoir-vitrine
AT371306B (de) Hoergeraet
ATA492281A (de) Karniese
ATA119581A (de) Zweibein

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: JOHN WYETH & BROTHER LTD

Effective date: 19890731